8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 8-K

____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2020

____________________________

Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)

____________________________

Delaware		001-36189	20-4327508
(State or other jurisdiction of incorporation)		(Commission File Number)	(I.R.S. Employer Identification No.)
11075 Roselle Street			92121
San Diego	California		(Zip Code)
(Address of principal executive offices)

 Registrant’s telephone number, including area code: (858) 366-6900

N/A

(Former name or former address, if changed since last report)

____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Symbol	Name of Exchange on Which Registered
Common Stock, par value $0.001 per share	TNDM	NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

____________________________

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 29, 2020, Tandem Diabetes Care, Inc. (the "Company") announced that Peyton Howell, age 53, was elected to the Company’s Board of Directors (the “Board”) effective August 3, 2020. Ms. Howell will serve as a Class III director, with a term that expires at the Annual Meeting of Stockholders of the Company to be held in 2022 or until her earlier resignation or removal. The Board has affirmatively determined that Ms. Howell qualifies as an “independent director” under the NASDAQ Listing Rules.

Ms. Howell is currently the Chief Commercial and Strategy Officer at Parexel International, a leading life sciences clinical research organization. Prior to her current position, she was Executive Vice President and President of Health Systems and Specialty Care as well as Global Sourcing and Manufacturing Relations at AmerisourceBergen. Ms. Howell also served as the Director of the AmerisourceBergen Foundation during this time. Ms. Howell received a B.A. in Speech Communication from The University of Illinois at Urbana-Champaign and a Master of Health Administration from The Ohio State University.

We believe Ms. Howell’s experience in reimbursement and in executive management of companies in the healthcare industry, brings to our board critical skills related to scaling complex organizations and strategic planning that qualify her to serve as one of our directors.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number	Description
99.1	Press release of Tandem Diabetes Care, Inc. dated July 29, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.
By:	/s/ David B. Berger
	David B. Berger
	Executive Vice President, Chief Legal & Compliance Officer

Date: July 30, 2020

EX-99.1

Exhibit 99.1

Media Contact:

Steve Sabicer

714-907-6264

ssabicer@thesabicergroup.com

Investor Contact:

Susan Morrison

858-366-6900 x7005

IR@tandemdiabetes.com

FOR IMMEDIATE RELEASE

Tandem Diabetes Care Appoints Peyton Howell to Board of Directors

San Diego, July 29, 2020 –Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Peyton Howell as an independent member of its board of directors effective August 3, 2020. Ms. Howell brings to the Tandem board extensive reimbursement and health insurance experience across a broad range of disease states in the in-hospital, pharmacy and home care settings.

“Peyton brings incredible value to our Board, drawing on more than 25 years of broad healthcare and leadership experience,” said John Sheridan, president and CEO, Tandem Diabetes Care. “Her appointment reflects our commitment to ensuring that we have a broad mix of skills and perspectives on Tandem’s board, and we are confident she will provide valuable insight as we continue to execute our strategy to lead in insulin therapy management.”

Ms. Howell is currently the Chief Commercial and Strategy Officer at Parexel International, a leading life sciences clinical research organization. As part of her role, she leads a diabetes reimbursement consulting team that provides reimbursement support and patient assistance for a continuous glucose monitor manufacturer. Prior to her current position, she was Executive Vice President and President of Health Systems and Specialty Care as well as Global Sourcing and Manufacturing Relations at AmerisourceBergen.

Ms. Howell is a recognized national speaker on health policy and reimbursement issues. She has served as Director of the AmerisourceBergen Foundation, the National Association of Chain Drug Stores Foundation, and the Healthcare Distribution Alliance Foundation. Ms. Howell received a B.A. in Speech Communication from The University of Illinois, Champaign and a Masters of Health Administration from The Ohio State University.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

1

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

# # #

2

XML

Cover Page Cover Page	Jul. 29, 2020
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jul. 29, 2020
Entity Registrant Name	Tandem Diabetes Care, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-36189
Entity Tax Identification Number	20-4327508
Entity Address, Address Line One	11075 Roselle Street
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	366-6900
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TNDM
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001438133